Stock Data
$0.33 (0.66%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
TG Therapeutics Inc is a biopharmaceutical company focused on creating innovative treatments for B-cell mediated diseases, such as multiple sclerosis and various forms of lymphoma. It markets BRIUMVI, a treatment for multiple sclerosis, and has a pipeline of potential therapies, including Umbralisib for lymphoma and TG-1701, a targeted cancer treatment. With a commitment to advancing care, TG Therapeutics collaborates with several partners to enhance its research and development efforts. Founded in 1993, the company is headquartered in Morrisville, North Carolina.
BRIUMVI's commercial muscle delivered 70% revenue growth and pushed TG Therapeutics to raise full-year guidance to $950M, but a cash-incinerating R&D ramp to develop subcutaneous formulations crushed earnings per share to $0.05, missing consensus by 89%.
0 Articles
No articles found for TG Therapeutics.
Our top personal finance-related articles today. Your wallet will thank you later.
